Compare IDEXX Laboratories, Inc. (IDXX) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Ralph Lauren Corp — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Ralph Lauren Corp trades at $398 (market cap $23.70B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Ralph Lauren Corp pays a 0.94% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | RL | |
|---|---|---|
Market Cap | $46.22B | $23.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $414.25 |
52-Week Low | $526.44 | $285.35 |
Enterprise Value | $47.12B | $24.76B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Ralph Lauren (RL) trades at $396.34, down 2.59% on the day, yet maintains strong fundamentals with consistent earnings beats and robust profitability. The stock exhibits a bullish technical trend, supported by positive analyst sentiment and a consensus price target of $456.50. Recent quarters show revenue growth and margin expansion, with Q1 2027 results exceeding expectations, reinforcing the company's brand resilience and strategic execution.
The outlook for RL remains favorable, driven by earnings momentum and global demand, though risks include consumer spending volatility and competitive pressures. With 66% of analysts rating it a Buy and institutional confidence high, the stock presents a growth opportunity, but investors should monitor macroeconomic headwinds that could impact discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
